Single-Blind, Controlled Safety and Immunogenicity Study of Recombinant MVA Virus to Treat HIV Infection

NCT00390078 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: MVA-mBN32
BIOLOGICAL: IMVAMUNE

Sponsor

Bavarian Nordic

Collaborators

[object Object]